Common issues include nausea, vomiting, diarrhea, and constipation, which are typically mild to moderate and most frequent during dose escalation
Inflammatory cytokines in ovarian cancer cells, including tumor necrosis factor- (TNF-) and interleukin-1 (IL-1), promote malignant progressionsuch as tumor cell migration and invasionby upregulating the expression of vascular cell adhesion molecule-1 (VCAM-1) and ICAM-1 [79,80,81,82]
The company says the decision is based on the SOUL trial, which showed that RYBELSUS lowered the risk of these events compared with placebo when added to standard diabetes and cardiovascular care
To ensure the comprehensiveness of the search, the reference lists of all eligible articles and relevant systematic reviews were also manually screened for additional studies
When a Patient Should Discuss Heart Risk Before GLP-1 Therapy Patients should discuss cardiovascular risk before starting GLP-1 therapy if they have a history of heart attack, stroke, coronary artery disease, stents, heart failure, high blood pressure, high cholesterol, diabetes, kidney disease, sleep apnea, fatty liver disease, or a strong family history of heart disease
